Prime time for base editing in the mitochondria

Morgan, Michael; Lange, Lucas; Schambach, Axel

doi:10.1038/s41392-022-01068-x

Cited by 3 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Employing small molecule drugs or gene editing techniques to correct these genetic anomalies could restore mitochondrial function and impede tumor growth. Additionally, the use of metabolic modulators may augment the efficacy of chemotherapy and immunotherapy ( 97 ).…”

Section: Discussionmentioning

confidence: 99%

Illuminating the immunological landscape: mitochondrial gene defects in pancreatic cancer through a multiomics lens

Chi,

Su,

Yan

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

This comprehensive review delves into the complex interplay between mitochondrial gene defects and pancreatic cancer pathogenesis through a multiomics approach. By amalgamating data from genomic, transcriptomic, proteomic, and metabolomic studies, we dissected the mechanisms by which mitochondrial genetic variations dictate cancer progression. Emphasis has been placed on the roles of these genes in altering cellular metabolic processes, signal transduction pathways, and immune system interactions. We further explored how these findings could refine therapeutic interventions, with a particular focus on precision medicine applications. This analysis not only fills pivotal knowledge gaps about mitochondrial anomalies in pancreatic cancer but also paves the way for future investigations into personalized therapy options. This finding underscores the crucial nexus between mitochondrial genetics and oncological immunology, opening new avenues for targeted cancer treatment strategies.

show abstract

Section: Discussionmentioning

confidence: 99%

Illuminating the immunological landscape: mitochondrial gene defects in pancreatic cancer through a multiomics lens

Chi,

Su,

Yan

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Given the limitations in current therapeutics in patients with LHON, the concept of mitochondrial genetic engineering presents a novel and exciting focus. Gene editing tools such as zinc-finger nucleases (mitoZFN) and transcription activator-like effector nucleases (MitoTALENs) have been shown to eliminate mutant mtDNA and shift heteroplasmy [ 84 ]. Recent advancements within the field have led to a new approach, mitochondrial base editing.…”

Section: Chronic Phasementioning

confidence: 99%

Solutions to a Radical Problem: Overview of Current and Future Treatment Strategies in Leber’s Hereditary Opic Neuropathy

Spiegel

Sadun

2022

IJMS

View full text Add to dashboard Cite

Leber’s Hereditary Optic Neuropathy (LHON) is the most common primary mitochondrial DNA disorder. It is characterized by bilateral severe central subacute vision loss due to specific loss of Retinal Ganglion Cells and their axons. Historically, treatment options have been quite limited, but ongoing clinical trials show promise, with significant advances being made in the testing of free radical scavengers and gene therapy. In this review, we summarize management strategies and rational of treatment based on current insights from molecular research. This includes preventative recommendations for unaffected genetic carriers, current medical and supportive treatments for those affected, and emerging evidence for future potential therapeutics.

show abstract

Exploring treatment options in cancer: tumor treatment strategies

Liu,

Zhou,

Tan

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

Traditional therapeutic approaches such as chemotherapy and radiation therapy have burdened cancer patients with onerous physical and psychological challenges. Encouragingly, the landscape of tumor treatment has undergone a comprehensive and remarkable transformation. Emerging as fervently pursued modalities are small molecule targeted agents, antibody-drug conjugates (ADCs), cell-based therapies, and gene therapy. These cutting-edge treatment modalities not only afford personalized and precise tumor targeting, but also provide patients with enhanced therapeutic comfort and the potential to impede disease progression. Nonetheless, it is acknowledged that these therapeutic strategies still harbour untapped potential for further advancement. Gaining a comprehensive understanding of the merits and limitations of these treatment modalities holds the promise of offering novel perspectives for clinical practice and foundational research endeavours. In this review, we discussed the different treatment modalities, including small molecule targeted drugs, peptide drugs, antibody drugs, cell therapy, and gene therapy. It will provide a detailed explanation of each method, addressing their status of development, clinical challenges, and potential solutions. The aim is to assist clinicians and researchers in gaining a deeper understanding of these diverse treatment options, enabling them to carry out effective treatment and advance their research more efficiently.

show abstract

Prime time for base editing in the mitochondria

Cited by 3 publications

References 5 publications

Illuminating the immunological landscape: mitochondrial gene defects in pancreatic cancer through a multiomics lens

Illuminating the immunological landscape: mitochondrial gene defects in pancreatic cancer through a multiomics lens

Solutions to a Radical Problem: Overview of Current and Future Treatment Strategies in Leber’s Hereditary Opic Neuropathy

Exploring treatment options in cancer: tumor treatment strategies

Contact Info

Product

Resources

About